Bayer AG is considering halting Roundup sales to individual consumers as the German pharmaceutical giant negotiates a deal to resolve U.S. litigation over the controversial weed killer, a German newspaper reported.
Bayer is mulling the move to help settle claims the herbicide causes cancer, Handelsblatt reported Thursday, citing people familiar with the matter. While households generate only about 10% of the product’s revenue, they make up most of the plaintiffs, according to Handelsblatt.
Bayer declined to comment on the report.
Lawsuits claiming Roundup causes cancer have surged since a trio of U.S. jury verdicts awarded plaintiffs almost $2.5 billion, increasing ...